Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AKTX | US
0.42
10.90%
Healthcare
Biotechnology
30/06/2024
13/04/2026
4.25
3.99
4.25
3.78
Akari Therapeutics Plc a clinical-stage biopharmaceutical company focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities including paroxysmal nocturnal hemoglobinuria Guillain-Barré syndrome hematopoietic stem cell transplant-associated thrombotic microangiopathy and bullous pemphigoid as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London the United Kingdom.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
20875.3%1 month
14767.3%3 months
8315.9%6 months
5904.4%-
-
3.07
-0.27
0.20
-0.06
-
-
-18.08M
51.58M
51.58M
-
-
-
-
-1.28K
2.26
0.41
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
5.38
Range1M
5.38
Range3M
5.38
Rel. volume
0.04
Price X volume
59.27K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| ImmuCell Corporation | ICCC | Biotechnology | 7.11 | 55.69M | 0.49% | n/a | 67.52% |
| PEPG | PEPG | Biotechnology | 1.69 | 55.08M | 3.05% | n/a | 12.52% |
| THL Credit Inc. 6.75% Notes du | TCRX | Biotechnology | 1.02 | 54.03M | -2.86% | n/a | 35.68% |
| TPST | TPST | Biotechnology | 2.14 | 53.94M | 4.39% | n/a | 119.58% |
| Sangamo Therapeutics Inc | SGMO | Biotechnology | 0.257 | 53.51M | 2.31% | n/a | 122.82% |
| OKYO Pharma Limited | OKYO | Biotechnology | 1.53 | 51.77M | 1.32% | n/a | -107.88% |
| Clene Nanomedicine Inc | CLNN | Biotechnology | 6.48 | 51.59M | 6.06% | n/a | -6472.02% |
| Acrivon Therapeutics Inc. | ACRV | Biotechnology | 1.61 | 49.87M | 3.21% | n/a | 1.95% |
| Tenax Therapeutics Inc | TENX | Biotechnology | 14.5 | 49.43M | 0.52% | n/a | 3.14% |
| Mereo BioPharma Group plc | MREO | Biotechnology | 0.32 | 49.23M | -2.74% | n/a | 7.83% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 10.4 | 15.84M | -11.56% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.8799 | 12.86M | -18.53% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6 | 11.59M | -0.17% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.33 | 3.40M | -0.75% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2276 | 2.17M | -10.25% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.07 | 1.14M | -0.96% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.06 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.07 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 8,315.89 | 72.80 | Riskier |
| Debt to Equity | -0.27 | -1.23 | Expensive |
| Debt to Assets | 0.20 | 0.25 | Cheaper |
| Market Cap | 51.58M | 3.66B | Emerging |